X

Trial Profile

Sequential Treatment With Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Lenalidomide (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

04 Dec 2018 Results assessing Computational Biology Modeling Analysis of Azacitidine (AZA) and Lenalidomide in acute myeloid leukemia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
03 Jan 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com